Epidemiology of ataxia and hereditary spastic paraplegia in Spain: A cross-sectional study

Male Cerebellar Ataxia Medicina Epidemiology España Hereditary spastic paraplegia 03 medical and health sciences Genetic map 0302 clinical medicine Genetics Epidemiología Humans RC346-429 Movement disorders Neurología Retrospective Studies Ataxias Paraparesias espásticas hereditarias Spastic Paraplegia, Hereditary Trastorns motors Middle Aged Genética 3. Good health Nervous system-Diseases Cross-Sectional Studies Neurology Spain Sistema nervioso-Enfermedades Medicine Mapa genético Ataxia Female Neurology. Diseases of the nervous system
DOI: 10.1016/j.nrleng.2023.04.003 Publication Date: 2023-04-28T09:07:23Z
ABSTRACT
Ataxia and hereditary spastic paraplegia are rare neurodegenerative syndromes. We aimed to determine the prevalence of these disorders in Spain in 2019.We conducted a cross-sectional, multicentre, retrospective, descriptive study of patients with ataxia and hereditary spastic paraplegia in Spain between March 2018 and December 2019.We gathered data from a total of 1933 patients from 11 autonomous communities, provided by 47 neurologists or geneticists. Mean (SD) age in our sample was 53.64 (20.51) years; 938 patients were men (48.5%) and 995 were women (51.5%). The genetic defect was unidentified in 920 patients (47.6%). A total of 1371 patients (70.9%) had ataxia and 562 (29.1%) had hereditary spastic paraplegia. Prevalence rates for ataxia and hereditary spastic paraplegia were estimated at 5.48 and 2.24 cases per 100 000 population, respectively. The most frequent type of dominant ataxia in our sample was SCA3, and the most frequent recessive ataxia was Friedreich ataxia. The most frequent type of dominant hereditary spastic paraplegia in our sample was SPG4, and the most frequent recessive type was SPG7.In our sample, the estimated prevalence of ataxia and hereditary spastic paraplegia was 7.73 cases per 100 000 population. This rate is similar to those reported for other countries. Genetic diagnosis was not available in 47.6% of cases. Despite these limitations, our study provides useful data for estimating the necessary healthcare resources for these patients, raising awareness of these diseases, determining the most frequent causal mutations for local screening programmes, and promoting the development of clinical trials.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (28)
CITATIONS (1)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....